alcaftadine 2.5 MG/ML Ophthalmic Solution

INDICATIONS AND USAGE LASTACAFT ® is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. LASTACAFT ® is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis. ( 1 )

DOSAGE AND ADMINISTRATION Instill one drop in each eye once daily. If more than 1 topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart. Instill one drop in each eye once daily. ( 2 )

WARNINGS AND PRECAUTIONS • Potential for Eye Injury and Contamination : To minimize the risk of eye injury and contamination, do not touch dropper tip to eyelids and surrounding areas, or any other surface. Keep bottle tightly closed when not in use. ( 5.1 ) • Contact Lens Wear: LASTACAFT ® should not be used to treat contact lens-related irritation. Remove contact lenses prior to instillation of LASTACAFT ® . ( 5.2 ) 5.1 Potential for Eye Injury and Contamination To minimize eye injury and contamination of the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. 5.2 Contact Lens Use Patients should be advised not to wear a contact lens if their eye is red. LASTACAFT ® should not be used to treat contact lens-related irritation. LASTACAFT ® should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of LASTACAFT ® . The preservative in LASTACAFT ® , benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of LASTACAFT ® .

CONTRAINDICATIONS LASTACAFT ® is contraindicated in patients with hypersensitivity to any component in the product. Hypersensitivity ( 4 )

Mechanism of Action Alcaftadine is an H 1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.